{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:23:50Z","timestamp":1795033430795,"version":"4.10.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024207","name":"Angelini Pharma Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s40120-026-01039-2","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:16:18Z","timestamp":1790090178000},"page":"2845-2857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Neurologists in the Management of Uncontrolled Epilepsy in Spain: Opportunities for Optimization"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-1064","authenticated-orcid":false,"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7103-3737","authenticated-orcid":false,"given":"Luis","family":"Lobato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1055","authenticated-orcid":false,"given":"Javier","family":"Riancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8610-1467","authenticated-orcid":false,"given":"Juan J.","family":"Poza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-3365","authenticated-orcid":false,"given":"\u00c1ngel","family":"Aledo-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"1039_CR1","unstructured":"Epilepsy. World Heal. Organ. Factsheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/epilepsy. Accessed 19 Mar 2024."},{"key":"1039_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108222","volume":"122","author":"V Villanueva","year":"2021","unstructured":"Villanueva V, Carre\u00f1o M, Gil-Nagel A, et al. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA). Epilepsy Behav. 2021;122:108222. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108222.","journal-title":"Epilepsy Behav"},{"key":"1039_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.33393\/grhta.2022.2427","volume":"9","author":"FS Mennini","year":"2022","unstructured":"Mennini FS, Sciattella P, Scortichini M. Socio-economic impact of epilepsy in Italy. Glob Reg Health Technol Assess. 2022;9:10\u20133. https:\/\/doi.org\/10.33393\/grhta.2022.2427.","journal-title":"Glob Reg Health Technol Assess"},{"key":"1039_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2589","volume":"12","author":"P Ioannou","year":"2022","unstructured":"Ioannou P, Foster DL, Sander JW, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12:1\u201311. https:\/\/doi.org\/10.1002\/brb3.2589.","journal-title":"Brain Behav"},{"key":"1039_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejpn.2024.10.010","volume":"53","author":"E Freeman-Jones","year":"2024","unstructured":"Freeman-Jones E, Wilson G, Eldred C, et al. Caregiver burden and therapeutic needs in Dravet syndrome - a national UK cross-sectional questionnaire study. Eur J Paediatr Neurol. 2024;53:138\u201343. https:\/\/doi.org\/10.1016\/j.ejpn.2024.10.010.","journal-title":"Eur J Paediatr Neurol"},{"key":"1039_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/JMDH.S69300","volume":"7","author":"PA Gibson","year":"2014","unstructured":"Gibson PA. Lennox-Gastaut syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc. 2014;7:441\u20138. https:\/\/doi.org\/10.2147\/JMDH.S69300.","journal-title":"J Multidiscip Healthc"},{"key":"1039_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/epi.13723","volume":"58","author":"CB Josephson","year":"2017","unstructured":"Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58:764\u201371. https:\/\/doi.org\/10.1111\/epi.13723.","journal-title":"Epilepsia"},{"key":"1039_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia"},{"key":"1039_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279\u201386. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949.","journal-title":"JAMA Neurol"},{"key":"1039_CR10","unstructured":"Ernst & Young SL. Epilepsia en acci\u00f3n. Situaci\u00f3n actual y propuestas de intervenci\u00f3n para mejorarla vida de las personas que viven con epilepsia. 2018. https:\/\/www.senep.es\/images\/site\/Epilepsia_en_Accion.pdf. Accessed 2018."},{"key":"1039_CR11","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/epi4.12984","volume":"9","author":"JJ Poza","year":"2024","unstructured":"Poza JJ, Gobbo M, Palanca C\u00e1mara M, FEDE, P\u00e9rez-Domper P, Aledo-Serrano \u00c1. Key steps and barriers in the journey of patients with epilepsy through the National Healthcare System in Spain: the EPIPASS qualitative study. Epilepsia Open. 2024;9:1731\u201344. https:\/\/doi.org\/10.1002\/epi4.12984.","journal-title":"Epilepsia Open"},{"key":"1039_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","volume":"43","author":"GL Birbeck","year":"2002","unstructured":"Birbeck GL, Hays RD, Cui X, Vickrey BG. Seizure reduction and quality of life provements in people with epilepsy. Epilepsia. 2002;43:535\u20138. https:\/\/doi.org\/10.1046\/j.1528-1157.2002.32201.x.","journal-title":"Epilepsia"},{"key":"1039_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16107","volume":"31","author":"E M\u00e9n\u00e9tr\u00e9","year":"2024","unstructured":"M\u00e9n\u00e9tr\u00e9 E, De Stefano P, Megevand P, et al. Antiseizure medication \u226448\u00a0hours portends better prognosis in new-onset epilepsy. Eur J Neurol. 2024;31:e16107. https:\/\/doi.org\/10.1111\/ene.16107.","journal-title":"Eur J Neurol"},{"key":"1039_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1136\/jnnp.55.6.497","volume":"55","author":"RA Grunewald","year":"1992","unstructured":"Grunewald RA, Chroni E, Panayiotopoulos CP. Delayed diagnosis of juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry. 1992;55:497\u20139. https:\/\/doi.org\/10.1136\/jnnp.55.6.497.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1039_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/qjmed\/92.1.15","volume":"92","author":"D Smith","year":"1999","unstructured":"Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM. 1999;92:15\u201323. https:\/\/doi.org\/10.1093\/qjmed\/92.1.15.","journal-title":"QJM"},{"key":"1039_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fepid.2022.976039","volume":"2","author":"J Pellinen","year":"2022","unstructured":"Pellinen J. Treatment gaps in epilepsy. Front Epidemiol. 2022;2:976039. https:\/\/doi.org\/10.3389\/fepid.2022.976039.","journal-title":"Front Epidemiol"},{"key":"1039_CR17","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/epi.17721","volume":"64","author":"P Jiruska","year":"2023","unstructured":"Jiruska P, Freestone D, Gnatkovsky V, Wang Y. An update on the seizures beget seizures theory. Epilepsia. 2023;64:S13-24. https:\/\/doi.org\/10.1111\/epi.17721.","journal-title":"Epilepsia"},{"key":"1039_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.seizure.2019.07.002","volume":"71","author":"GL Fialho","year":"2019","unstructured":"Fialho GL, Wolf P, Walz R, Lin K. Epilepsy and ultra-structural heart changes: the role of catecholaminergic toxicity and myocardial fibrosis. What can we learn from cardiology? Seizure. 2019;71:105\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2019.07.002.","journal-title":"Seizure"},{"key":"1039_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100696","volume":"27","author":"RL Verrier","year":"2024","unstructured":"Verrier RL, Schachter SC. The Epileptic Heart Syndrome: epidemiology, pathophysiology and clinical detection. Epilepsy Behav Reports. 2024;27:100696. https:\/\/doi.org\/10.1016\/j.ebr.2024.100696.","journal-title":"Epilepsy Behav Reports"},{"key":"1039_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-026-00993-1","author":"L Lobato","year":"2026","unstructured":"Lobato L, Riancho J, Garc\u00eda-Azor\u00edn D, P\u00e9rez-Domper P, Aledo-Serrano \u00c1, Poza JJ. Neurologists\u2019 views on the management of uncontrolled epilepsy in Spain: a preliminary survey. Neurol Ther. 2026. https:\/\/doi.org\/10.1007\/s40120-026-00993-1.","journal-title":"Neurol Ther"},{"key":"1039_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ncl.2022.03.012","volume":"40","author":"DL Paulo","year":"2022","unstructured":"Paulo DL, Ball TJ, Englot DJ. Emerging technologies for epilepsy surgery. Neurol Clin. 2022;40:849\u201367. https:\/\/doi.org\/10.1016\/j.ncl.2022.03.012.","journal-title":"Neurol Clin"},{"key":"1039_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/epi.16738","volume":"62","author":"M Hrabok","year":"2021","unstructured":"Hrabok M, Engbers JDT, Wiebe S, et al. Primary care electronic medical records can be used to predict risk and identify potentially modifiable factors for early and late death in adult onset epilepsy. Epilepsia. 2021;62:51\u201360. https:\/\/doi.org\/10.1111\/epi.16738.","journal-title":"Epilepsia"},{"key":"1039_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2165\/00023210-200519110-00001","volume":"19","author":"E Perucca","year":"2005","unstructured":"Perucca E, Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs. 2005;19:897\u2013908. https:\/\/doi.org\/10.2165\/00023210-200519110-00001.","journal-title":"CNS Drugs"},{"key":"1039_CR24","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1468-1331.2008.02260.x","volume":"15","author":"FA Chowdhury","year":"2008","unstructured":"Chowdhury FA, Nashef L, Elwes RDC. Misdiagnosis in epilepsy: a review and recognition of diagnostic uncertainty. Eur J Neurol. 2008;15:1034\u201342. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02260.x.","journal-title":"Eur J Neurol"},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.seizure.2016.11.029","volume":"44","author":"MM Oto","year":"2017","unstructured":"Oto MM. The misdiagnosis of epilepsy: appraising risks and managing uncertainty. Seizure. 2017;44:143\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2016.11.029.","journal-title":"Seizure"},{"key":"1039_CR26","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1001\/amajethics.2020.416","volume":"22","author":"AT Yahanda","year":"2020","unstructured":"Yahanda AT, Mozersky J. What\u2019s the role of time in shared decision making? AMA J Ethics. 2020;22:E416-422. https:\/\/doi.org\/10.1001\/amajethics.2020.416.","journal-title":"AMA J Ethics"},{"key":"1039_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.yebeh.2018.10.013","volume":"89","author":"S An","year":"2018","unstructured":"An S, Malhotra K, Dilley C, et al. Predicting drug-resistant epilepsy \u2014 a machine learning approach based on administrative claims data. Epilepsy Behav. 2018;89:118\u201325. https:\/\/doi.org\/10.1016\/j.yebeh.2018.10.013.","journal-title":"Epilepsy Behav"},{"key":"1039_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120766","volume":"452","author":"B Mesraoua","year":"2023","unstructured":"Mesraoua B, Brigo F, Lattanzi S, Abou-Khalil B, Al Hail H, Asadi-Pooya AA. Drug-resistant epilepsy: definition, pathophysiology, and management. J Neurol Sci. 2023;452:120766. https:\/\/doi.org\/10.1016\/j.jns.2023.120766.","journal-title":"J Neurol Sci"},{"key":"1039_CR29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40263-024-01130-y","volume":"38","author":"P Klein","year":"2024","unstructured":"Klein P, Friedman D, Kwan P. Recent advances in pharmacologic treatments of drug-resistant epilepsy: breakthrough in sight. CNS Drugs. 2024;38:949\u201360. https:\/\/doi.org\/10.1007\/s40263-024-01130-y.","journal-title":"CNS Drugs"},{"key":"1039_CR30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/epi.17564","volume":"64","author":"P Klein","year":"2023","unstructured":"Klein P, Krauss GL, Steinhoff BJ, Devinsky O, Sperling MR. Failure to use new breakthrough treatments for epilepsy. Epilepsia. 2023;64:1458\u201365. https:\/\/doi.org\/10.1111\/epi.17564.","journal-title":"Epilepsia"},{"key":"1039_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","volume":"118","author":"S Mulheron","year":"2024","unstructured":"Mulheron S, Leahy TP, McStravick M, Doran R, Delanty N. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure Eur J Epilepsy. 2024;118:80\u201390. https:\/\/doi.org\/10.1016\/j.seizure.2024.04.004.","journal-title":"Seizure Eur J Epilepsy"},{"key":"1039_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yebeh.2019.05.020","volume":"97","author":"A Sharobeam","year":"2019","unstructured":"Sharobeam A, Mamun A, Kwok A, Zandiehvakili M, Beran RG. Management and attitudes toward patients with epilepsy in general practice: how far have we come in three decades? Epilepsy Behav. 2019;97:92\u20135. https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.020.","journal-title":"Epilepsy Behav"},{"key":"1039_CR33","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1007\/s00415-023-11958-x","volume":"270","author":"R Toledano","year":"2023","unstructured":"Toledano R, Villanueva V, Toledo M, Sabaniego J, P\u00e9rez-Domper P. Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis. J Neurol. 2023;270:5945\u201357. https:\/\/doi.org\/10.1007\/s00415-023-11958-x.","journal-title":"J Neurol"},{"key":"1039_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14030255","volume":"14","author":"A Jopowicz","year":"2024","unstructured":"Jopowicz A, Piechal A, Bronisz E, Kurkowska-Jastrz\u0119bska I. Adherence to epilepsy\u2019s medical recommendations. Brain Sci. 2024;14:255. https:\/\/doi.org\/10.3390\/brainsci14030255.","journal-title":"Brain Sci"},{"key":"1039_CR35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yebeh.2017.05.018","volume":"73","author":"L Ridsdale","year":"2017","unstructured":"Ridsdale L, Kwan I, Bee N. The effectiveness of nurse-led care in epilepsy management: a systematic review. Epilepsy Behav. 2017;73:77\u201385.","journal-title":"Epilepsy Behav"},{"key":"1039_CR36","volume":"104","author":"V Villanueva","year":"2020","unstructured":"Villanueva V, Garc\u00eda M, L\u00f3pez M, Sanz P. The EPIPASS study: Impact of a structured nursing intervention on epilepsy care. Epilepsy Behav. 2020;104:106521.","journal-title":"Epilepsy Behav"},{"key":"1039_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18773\/austprescr.2024.001","volume":"47","author":"T Usherwood","year":"2024","unstructured":"Usherwood T. Therapeutic inertia. Aust Prescr. 2024;47:15\u20139. https:\/\/doi.org\/10.18773\/austprescr.2024.001.","journal-title":"Aust Prescr"},{"key":"1039_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jocn.2019.08.013","volume":"69","author":"C Sedney","year":"2019","unstructured":"Sedney C, Kurowski-Burt A, Smith M, Dekeseredy P, Grey C, Boo S. Therapeutic nihilism of neurological diseases: a comparative qualitative study. J Clin Neurosci. 2019;69:124\u201331. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.013.","journal-title":"J Clin Neurosci"},{"key":"1039_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s42494-026-00257-3","volume":"8","author":"BJ Steinhoff","year":"2026","unstructured":"Steinhoff BJ, Leach JP. Overtreatment and therapeutic nihilism in chronic epilepsy: a call to action! Acta Epileptol. 2026;8:18. https:\/\/doi.org\/10.1186\/s42494-026-00257-3.","journal-title":"Acta Epileptol"},{"key":"1039_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1212\/CPJ.0000000000001066","volume":"11","author":"PE Penovich","year":"2021","unstructured":"Penovich PE, Stern JM, Becker DA, et al. Epilepsy treatment complacency in patients, caregivers, and health care professionals. Neurol Clin Pract. 2021;11:377\u201384. https:\/\/doi.org\/10.1212\/CPJ.0000000000001066.","journal-title":"Neurol Clin Pract"},{"key":"1039_CR41","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/jnnp-2019-320883","volume":"90","author":"E Beghi","year":"2019","unstructured":"Beghi E, Beretta S, Carone D, et al. Prognostic patterns and predictors in epilepsy: a multicentre study (PRO-LONG). J Neurol Neurosurg Psychiatry. 2019;90:1276\u201385. https:\/\/doi.org\/10.1136\/jnnp-2019-320883.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1039_CR42","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/epi.16594","volume":"61","author":"BN Blond","year":"2020","unstructured":"Blond BN, Hirsch LJ, Mattson RH. Misperceptions on the chance of seizure freedom with antiseizure medications after two failed trials. Epilepsia. 2020;61:1789\u201390. https:\/\/doi.org\/10.1111\/epi.16594.","journal-title":"Epilepsia"},{"key":"1039_CR43","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","volume":"88","author":"C Harden","year":"2017","unstructured":"Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2017;88:1674\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000003685.","journal-title":"Neurology"},{"key":"1039_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/ane.12703","volume":"135","author":"N Malek","year":"2017","unstructured":"Malek N, Heath CA, Greene J. A review of medication adherence in people with epilepsy. Acta Neurol Scand. 2017;135:507\u201315. https:\/\/doi.org\/10.1111\/ane.12703.","journal-title":"Acta Neurol Scand"},{"key":"1039_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.33588\/rn.7808.2024079","volume":"78","author":"JJ Poza Aldea","year":"2024","unstructured":"Poza Aldea JJ. The importance of adherence to treatment in control of epilepsy. Rev Neurol. 2024;78:237. https:\/\/doi.org\/10.33588\/rn.7808.2024079.","journal-title":"Rev Neurol"},{"key":"1039_CR46","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","volume":"87","author":"S Gollwitzer","year":"2016","unstructured":"Gollwitzer S, Kostev K, Hagge M, Lang J, Graf W, Hamer HM. Nonadherence to antiepileptic drugs in Germany. Neurology. 2016;87:466\u201372. https:\/\/doi.org\/10.1212\/WNL.0000000000002791.","journal-title":"Neurology"},{"key":"1039_CR47","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296\u2013310. https:\/\/doi.org\/10.1016\/S0149-2918(01)80109-0.","journal-title":"Clin Ther"},{"key":"1039_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109484","volume":"149","author":"A Gonzalez","year":"2023","unstructured":"Gonzalez A, Pandey D, Digiannantonio N, Serafini A. Adherence to antiseizure medications in an underserved population with epilepsy. Epilepsy Behav. 2023;149:109484. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109484.","journal-title":"Epilepsy Behav"},{"key":"1039_CR49","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.aprim.2008.09.031","volume":"41","author":"T Dilla","year":"2009","unstructured":"Dilla T, Valladares A, Liz\u00e1n L, Sacrist\u00e1n JA. Adherencia y persistencia terap\u00e9utica: causas, consecuencias y estrategias de mejora. Aten Primaria. 2009;41:342\u20138. https:\/\/doi.org\/10.1016\/j.aprim.2008.09.031.","journal-title":"Aten Primaria"},{"key":"1039_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.02.001","volume":"122","author":"E Brodtkorb","year":"2016","unstructured":"Brodtkorb E, Samsonsen C, Sund JK, Br\u00e5then G, Helde G, Reimers A. Treatment non-adherence in pseudo-refractory epilepsy. Epilepsy Res. 2016;122:1\u20136. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.02.001.","journal-title":"Epilepsy Res"},{"key":"1039_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2023.100631","volume":"24","author":"K Andr\u00e9n","year":"2023","unstructured":"Andr\u00e9n K, Larsson D, Aszt\u00e9ly F, Zelano J. Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT). Epilepsy Behav Reports. 2023;24:100631. https:\/\/doi.org\/10.1016\/j.ebr.2023.100631.","journal-title":"Epilepsy Behav Reports"},{"key":"1039_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6718915","volume":"2020","author":"D Bhalla","year":"2020","unstructured":"Bhalla D, Lotfalinezhad E, Amini F, et al. Medication beliefs and adherence to antiseizure medications. Neurol Res Int. 2020;2020:1\u20139. https:\/\/doi.org\/10.1155\/2020\/6718915.","journal-title":"Neurol Res Int"},{"key":"1039_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-8-264","volume":"8","author":"JP Szaflarski","year":"2008","unstructured":"Szaflarski JP, Rackley AY, Lindsell CJ, Szaflarski M, Yates SL. Seizure control in patients with epilepsy: the physician vs. medication factors. BMC Health Serv Res. 2008;8:264. https:\/\/doi.org\/10.1186\/1472-6963-8-264.","journal-title":"BMC Health Serv Res"},{"key":"1039_CR54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.yebeh.2008.02.003","volume":"13","author":"AS Hakimi","year":"2008","unstructured":"Hakimi AS, Spanaki MV, Schuh LA, Smith BJ, Schultz L. A survey of neurologists\u2019 views on epilepsy surgery and medically refractory epilepsy. Epilepsy Behav. 2008;13:96\u2013101. https:\/\/doi.org\/10.1016\/j.yebeh.2008.02.003.","journal-title":"Epilepsy Behav"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01039-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:01:43Z","timestamp":1795032103000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01039-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luis Lobato has received honoraria for educational activities and\/or research funds from Angelini Pharma, Eisai, Jazz Pharmaceuticals, Neuraxpharm and UCB Pharma. Javier Riancho has received honoraria for educational activities and\/or research funds from Angelini Pharma, Bial, Eisai, Neuraxpharm, Nutricia, Sanofi and UCB Pharma. David Garc\u00eda Azor\u00edn has received personal compensation for consulting\/advising from the World Health Organization; held non-profit board memberships in the Spanish Society of Neurology and the European Union of Medical Specialists section of Neurology; received research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Spain; and had involvement through speaker\/travel grants and clinical trial participation with Teva, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Biohaven. Juan Jos\u00e9 Poza has received honoraria for advisory, educational activities and\/or research funds from Angelini Pharma, GlaxoSmithKline, Bial, Eisai, Jazz Pharmaceuticals, Neuraxpharm, Sanofi and UCB Pharma. \u00c1ngel Aledo Serrano has received honoraria for educational activities and\/or research funds from Angelini Pharma, Bial, Blueprint Genetics, Eisai, Health in Code, Jazz Pharmaceuticals, Neuraxpharm, Nutricia and UCB Pharma.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}